Export 36 results:
Author Title Type [ Year(Desc)]
Filters: Author is Oden, Neal L  [Clear All Filters]
2019
M. S. Ip, Oden, N. L., Scott, I. U., VanVeldhuisen, P. C., Blodi, B. A., Ghuman, T., and Baker, C. W., “Month 12 Outcomes After Treatment Change at Month 6 Among Poor Responders to Aflibercept or Bevacizumab in Eyes With Macular Edema Secondary to Central or Hemiretinal Vein Occlusion: A Secondary Analysis of the SCORE2 Study.”, JAMA Ophthalmol, vol. 137, no. 3, pp. 281-287, 2019.
I. U. Scott, Oden, N. L., VanVeldhuisen, P. C., Ip, M. S., Blodi, B. A., and Chan, C. K., “Month 24 Outcomes After Treatment Initiation With Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion: SCORE2 Report 10: A Secondary Analysis of the SCORE2 Randomized Clinical Trial.”, JAMA Ophthalmol, 2019.
I. U. Scott, VanVeldhuisen, P. C., Barton, F., Oden, N. L., Ip, M. S., Blodi, B. A., Worrall, M., and Fish, G. E., “Patient-Reported Visual Function Outcomes After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion: Preplanned Secondary Analysis of a Randomized Clinical Trial.”, JAMA Ophthalmol, 2019.
2020
R. Khurana, Hendrick, A., Van Veldhuisen, P., Scott, I. U., Blodi, B. A., Ip, M. S., and Oden, N. L., “Change in Area of Intraretinal Macular Hemorrhages in Aflibercept- and Bevacizumab-treated Central Retinal and Hemiretinal Vein Occlusions: A SCORE2 Subanalysis”, in 43rd Annual Macula Society, San Diego, CA, 2020.
A. Hendrick, VanVeldhuisen, P. C., Scott, I. U., King, J., Blodi, B. A., Ip, M. S., Khurana, R. N., and Oden, N. L., “SCORE2 Report 13: Intraretinal Hemorrhage Changes in Eyes With Central or Hemiretinal Vein Occlusion Managed With Aflibercept, Bevacizumab or Observation. Secondary Analysis of the SCORE and SCORE2 Clinical Trials.”, Am J Ophthalmol, vol. 222, pp. 185-193, 2020.
2021
R. N. Khurana, Oden, N. L., VanVeldhuisen, P. C., Scott, I. U., Blodi, B. A., and Ip, M. S., “Association between early and late response in eyes with central or hemiretinal vein occlusion treated with anti-VEGF agents : SCORE2 report 12: secondary analysis of the SCORE2 clinical trial.”, Graefes Arch Clin Exp Ophthalmol, vol. 239, no. 7, pp. 1839-1851, 2021.
A. A. Aref, Scott, I. U., VanVeldhuisen, P. C., King, J., Ip, M. S., Blodi, B. A., and Oden, N. L., “Intraocular Pressure-Related Events After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Report 16 on a Secondary Analysis of a Randomized Clinical Trial”, JAMA Ophthalmol, vol. 139, no. 12, pp. 1285-1291, 2021.
I. U. Scott, Oden, N. L., VanVeldhuisen, P. C., Ip, M. S., and Blodi, B. A., “SCORE2 Report 17: Macular Thickness Fluctuations in anti-VEGF-Treated Patients with Central or Hemiretinal Vein Occlusion”, Graefes Arch Clin Exp Ophthalmol, 2021.
2022
I. U. Scott, Oden, N. L., VanVeldhuisen, P. C., Ip, M. S., and Blodi, B. A., “Baseline Characteristics and Outcomes After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema in Participants with Hemiretinal Vein Occlusion Compared With Participants with Central Retinal Vein Occlusion (SCORE2) Report 18”, JAMA Ophthalmol, vol. 140, no. 5, pp. 458-464, 2022.
I. U. Scott, VanVeldhuisen, P. C., Oden, N. L., Ip, M. S., and Blodi, B. A., “Month 60 Outcomes After Treatment Initiation With Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion”, Am J Ophthalmol, vol. 240, pp. 330-341, 2022.
2023
I. U. Scott, Oden, N. L., VanVeldhuisen, P. C., Ip, M. S., and Blodi, B. A., “SCORE2 Report 20: Relationship of Treatment Discontinuation With Visual Acuity and Central Subfield Thickness Outcomes”, Am J Ophthalmol, vol. 248, pp. 157-163, 2023.